PRL 3195

Cat. No.:	HY-P4469
CAS No.:	341519-04-8
Molecular Formula:	$C_{58}H_{69}ClN_{12}O_9S_2$
Molecular Weight:	1177.83
Sequence:	{Phe<4Cl>}-{d-Cys}-{β-Ala<3-Py>}-{d-Trp}-{Lys<N2-Me>}-Thr-Cys-{2-Nal}-NH2 (Disulfide bridge:Cys2-Cys7)
Sequence Shortening:	{F<4Cl>}-{d-C}-{β-A<3-Py>}-{d-W}-{K<N2-Me>}-TC-{2-Nal}-NH2 (Disulfide bridge:Cys2-Cys7)
Target:	Somatostatin Receptor; Urotensin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	PRL 3195 is a somatostatin receptor antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst$_5$, sst$_2$, sst$_3$, sst$_1$ and sst$_4$, respectively)[1].			
IC_{50} & Target	hsst$_5$ 6 nM (Ki)	hsst$_2$ 17 nM (Ki)	hsst$_3$ 66 nM (Ki)	hsst$_1$ 1000 nM (Ki)
	hsst$_4$ 1000 nM (Ki)	rat urotensin II receptor 429 nM (Ki)	human urotensin II receptor 1846 nM (Ki)	
In Vitro	PRL 3195 inhibits human urotensin II-induced phasic oscillations of rat aorta with an ED_{50} of 24 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Rossowski WJ, et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002 Mar 8;438(3):159-70.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA